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HIGH DOSE-RATE BRACHYTHERAPY IN THE RADICAL 
TREATMENT OF CERVICAL CANCER. AN ANALYSIS OF 
DOSE EFFECTIVENESS AND INCIDENCE OF LATE 
RADIATION COMPLICATIONS
D. LONG, H. FRIEDRICH-NEL, L. GOEDHALS AND G. JOUBERT
ABSTRACT
Worldwide, uterine cervical cancer is one of the most frequently occurring 
cancers in women, with more than 80% of these cases occurring in developing 
countries. The South African screening policy and screening program, 
implemented in 2001, attempt to reduce this incidence of cervical cancer in 
South Africa. It is essential to treat these women with the best modalities 
available. This retrospective study focused specifically on the curative 
potential of radiotherapy administered to patients at the Oncology 
Department, Bloemfontein, since a new modality of high dose-rate 
intracavitary brachytherapy was implemented in 1994. Late radiation 
complications were also investigated.
Keywords: cervical cancer; radiotherapy; high-dose-rate brachytherapy; 
biologically effective dose; late radiation complications
1. INTRODUCTION
Radiotherapy plays an important role in the treatment of uterine cervical 
cancer, and a combination of external beam radiotherapy (EBRT) and high 
dose-rate (HDR)-intracavitary brachytherapy (ICBT) is the accepted mode of 
1
treatment.  Although a large number of fractionation schedules are used 
worldwide in treating cervical cancer, the optimal schedule has yet to be 
2
decided. Petereit and Pearcey  analyzed the fractionation schedules reported 
in 24 published articles and came to the conclusion that there was no optimal 
fractionation schedule available. They suggested that reasonable 
fractionation schedules should be based on single institutional experience 
with accurate reporting. A need exists, however, to deliver biologically 
effective doses of irradiation to ensure the highest probability of tumor control 
in the pelvis, with minimal late rectal complications. Organs at risk are the 
radiosensitive organs in or near the target volume. Careful monitoring of the 
biological doses for both the rectum and bladder is an important factor for 
3
minimizing late sequelae.  The sites of radiation-related complications most 
frequently noted in uterine cervical cancer radiotherapy are (a) rectum, most 
commonly the anterior rectal wall; (b) bladder, most commonly the posterior 
bladder wall; (c) vaginal vault; (d) sigmoid colon; (e) small bowel; (f) abdomen; 
(g) ureters; (h) skin; and (i) bone and hip.
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In April 1994, the Oncology Department, Universitas Annex, Bloemfontein, 
192
implemented a high dose-rate brachytherapy treatment system, an Ir 
Nucletron Microselectron afterloading source, using the ring applicator. The 
International Atomic Energy Agency (IAEA) has published recommendations 
192 4
specifically for implementing HDR Ir brachytherapy in developing countries.  
The IAEA recommendations and those of the American Brachytherapy 
5 6
Society,  based on the Patterns of Care studies,  were used as guidelines to 
develop a HDR-ICBT treatment protocol for patients with uterine cervical 
cancer (FIGO stages I-III) at the Oncology Department, Universitas Annex.
The initial staging system of uterine cervical cancer proposed in 1929 by a 
subcommittee of the League of Nations was revised in 1937 and 1950. These 
functions were taken over by the International Federation of Gynecologists 
and Obstetricians (FIGO) in collaboration with the World Health Organization 
7
(WHO) and the International Union Against Cancer.  It is imperative that the 
gynecologist and the radiation oncologist jointly stage the tumor in every 
patient with bimanual pelvic and rectal examination. In FIGO stage I, the 
cervical cancer is confined to the uterus; in stage II, the cancer invades 
beyond the uterus, but not the pelvic wall or the lower third of the vagina; and in 
stage III, the cervical cancer extends to the pelvic wall and/or involves lower 
third of the vagina and/or causes hydronephrosis or nonfunctional kidney. 
Tumor staging also depends on whether the regional lymph nodes are 
8
involved and whether the presence of distant metastases can be assessed.
The advent of HDR brachytherapy in the department brought a convenient 
treatment option for patients with uterine cervical cancer, permitting treatment 
of 10 to 15 patients weekly. The advantages of HDR brachytherapy include 
individualized dosimetry, outpatient treatment, a reduction in hospitalization 
costs, and elimination of radiation exposure of medical personnel.
The aim of the current study was to calculate the biologically effective dose 
(BED) for the fractionation schedule implemented at the Oncology 
Department since 1994, and to determine whether the fractionation schedule 
delivered BEDs that led to local tumor control without severe late radiation 
complications. Analysis of the treatment schedule, regarding the calculated 
BED, would indicate whether the total dose given to the planned tumor volume 
(PTV) by means of EBRT and the gross tumor volume (GTV) by means of 
HDR-ICBT, had led to local tumor control with negligible late toxicity to organs 
at risk, such as the rectum and bladder. To achieve tumor control with HDR 
brachytherapy, attention to the dose/fraction schedule and the normal tissue 
doses is mandatory. In general, the α/β values for tumor and early-responding 
tissues are approximately 10 (Gy ) and for late-responding tissues 3-5 (Gy ). 
10 3-5
The values derived are not actual doses, but biologically effective ones that 
8
take into consideration dose-rate and impact of fraction size.  The cumulative 
BEDs, calculated for the combination of EBRT and HDR-ICBT, to the tumor 
Gy  and the rectum Gy  for cervical cancer patients would enable the 
10 3
Oncology Department to compare BED values for the first time with those of 
83          
other institutions in South Africa and worldwide.
2. METHODS AND MATERIALS
2.1. Patient selection
Patients (n=696) diagnosed with FIGO stages I-III cervical cancer, who had 
completed their radiotherapy treatment (EBRT and HDR-ICBT) at the 
Oncology Department, were eligible to be included in this retrospective study. 
The treatment and follow-up details were analyzed and the patients were 
included if they were treated at the Department for FIGO stages I-III cervical 
cancer, received only radiotherapy (EBRT and HDR ICBT) as treatment 
modality, and had at least a two-year follow-up record for analysis of late 
radiation complications. Of the 696 patients, 348 patients did not receive their 
follow-up examinations in the Free State, 196 had follow-up periods of less 
than two years, and 58 did not have complete dosimetric data. Consequently, 
the data of 94 patients were included in the study. The patient information was 
entered into a data sheet designed for the study, and was pilot-tested on ten 
patient files. The study was approved by the Ethics Committee of the Faculty 
of Health Sciences, University of the Free State, Bloemfontein (ETOVS NR 
31/06).
2.2. Radiotherapy
Radiotherapy consisted of EBRT followed by HDR-ICBT. The EBRT was 
given over a six-week period, while the 4-6 fractions of HDR-ICBT were 
interdigitated (once weekly) into the EBRT treatment schedule. The overall 
duration of treatment ranged from 32 to 60 days (mean 41 days). Most of the 
patients (60%) received their EBRT treatment via the 6-MV photon beam 
accelerator (ELEKTA SL 75/6), whereas 37.2% of patients received 8-MV and 
3.2% of patients were treated via 15-MV photon beam. The technique used 
was by four-field-box with anterior, posterior and two lateral planned fields with 
classic limits. The standard prescribed doses of EBRT to the whole pelvis was 
50 Gy, consisting of 25 fractions of 2 Gy/fraction. The HDR brachytherapy was 
192
administered to all patients by utilizing a Ir Nucletron Microselectron 
afterloading unit. A medical physicist at the Oncology Department planned the 
HDR-ICBT treatment using the computerized planning program PLATO 
SYSTEM 3.3.1, version 2 (Nucletron International BV, The Netherlands). The 
standard prescribed dose for each HDR-ICBT treatment was 2 Gy/fraction to 
the highest rectum dose point. The mean dose per fraction to point A for the 94 
patients was 3.66 Gy (range 2.55 - 6.68 Gy; SD 1.03), and the mean value of 
the total dose administered to these patients during HDR-ICBT was 18 Gy.
The dose to point A differed for each patient due to different rectum positions 
during each HDR-ICBT treatment. Therefore, the dose to clinical point A (2 cm 
lateral and 2 cm superior of the cervical os) would vary as a function of the 
highest rectum dose point for each fraction given. The position of the rectum 
relative to the ring applicator was defined by an oncologist on the lateral 
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radiograph, and the dose distribution was normalized with respect to the 
maximum rectal dose. The rectal reference point according to the guidelines in 
the International Commission on Radiation Units and Measurements (ICRU) 
9
Report 38,  was therefore not used. The lateral X-ray film, which verified the 
placement of the ring applicator with regard to the barium-outlined rectum, 
was used by the physicist to portray the rectum dose points in a 2D-projection. 
Dosimetric planning of HDR-ICBT was performed in each application for all 
patients by a standard plan template, which was based on the definition of the 
Manchester System of point A. Standard plans were developed for each of the 
º º
ring applicator sets (45  or 60  degree sets) in use, and source dwell times and 
positions were adjusted to suit the dose distribution required for each 
individual patient. Pear-shaped distributions were required, therefore manual 
optimization was done. Consequently, no planned optimization was done and 
the prescribed dose was computed to point A. However, in some cases, the 
192
Ir dwell positions were altered from the standard plan template. These 
adjustments were necessary because of a dose escalation to the rectum 
caused by its position with regard to the central applicator. Figure 1 shows the 
standard calculated isodose distribution.
The dose effectiveness of the fractionation schedule was analyzed 
retrospectively by calculating the cumulative/total BED of the combination of 
EBRT and HDR-ICBT for FIGO stages I-III cervical cancer patients (Total BED 
= BEDEBRT + BEDHDR-ICBT). The linear quadratic model (LQ model), 
originally applied to fractionated radiotherapy by Fowler and Stern in 1960, 
was refined and expanded by Barendson in 1982 and Dale in 1985, and its use 
10
has been reviewed by Fowler.  The basic equation defines the amount of 
radiation damage, E, resulting from n high dose-rate fractions of size d each 
as:
 
(1)
Figure 1. Standard calculated isodose distribution based on the Manchester 
System. (Permission to use above figure has been duly granted.)
2.3. Biologically effective dose calculation
85          
(2)
The LQ model was used to calculate the biologically effective doses for all 
patients who met the inclusion criteria for this retrospective study. It is a 
mathematically simple way to quantify biological responses to different 
11
fractionation schedules.  Calculations of the BED of the fractionation 
schedule were done by the Department of Biostatistics, University of the Free 
State. On the basis of the LQ model, the cumulative BED to the tumor and the 
rectum, generated from the contribution of EBRT and HDR-ICBT, was 
calculated for all patients. The BED was calculated to the tumor (α/β = 10) and 
the rectum (α/β = 3) for both EBRT and HDR-ICBT. The cumulative BED to the 
tumor for each patient was the sum of the total EBRT midline dose (50 Gy) and 
the total point A dose of HDR-ICBT. The cumulative BED to the rectum for each 
patient was the sum of the EBRT dose, determined by dose-volume 
histograms, and a dose of 2 Gy/fraction prescribed to the highest rectum dose 
point for HDR-ICBT.
2.4. Patient follow-up and scoring criteria for late radiation 
complications
The patients were followed-up by radiation oncologists by means of a clinical 
examination one month after radiotherapy had been completed. Thereafter, 
the patients were followed-up every three months for the first year and every 
four months for the second and third year. Follow-up procedures included a 
clinical (pelvic) examination and cervical Papanicolaou smears. When central 
and/or parametrial recurrence was suspected by pelvic examination and/or 
Papanicolaou smears, a biopsy was taken for confirmation. A chest 
radiograph was taken annually. Other imaging studies such as computer 
tomography, ultrasonography and bone scintigraphy, were not routinely 
performed.
The retrospective scoring of the late radiation complications was done by 
using the information notes of the radiation oncologists taken during the 
patients' follow-up examinations. Late radiation complications were scored 
according to the Radiation Therapy Oncology Group (RTOG)/European 
12
Organization for Research and Treatment of Cancer (EORTC).
2.5. Statistical analysis
Results were summarized by frequencies and percentages (categorical 
variables) and means, standard deviations, median, minimum and maximum 
(numerical variables). The software used was SAS 9.1.3 Service Pack 3. 
Survival analysis was used to determine the probability of recurrence, late 
complications and metastases at various time points. The cumulative BED 
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values of the combination of EBRT and HDR-ICBT were investigated using 
the log-rank test based on survival analysis. The data collected for this 
retrospective study was processed by the Department of Biostatistics, 
University of the Free State, Bloemfontein.
3. RESULTS
3.1. Patient demographics
The mean age of the 94 patients was 55 years (range 26 -76 years; SD 9.5). 
HIV tests revealed that 87 (92.6%) patients were HIV-negative and seven 
(7.5%) HIV-positive. All patients were staged according to the FIGO staging 
for uterine cervical cancer. The FIGO staging for the 94 patients is given in 
Table 1. Median follow-up time for the 94 patients was 40 months (3.3 years), 
with a range of 24-93 months (7.8 years).
3.2. Treatment results
Dose effectiveness-tumor recurrence
Survival was 100% for all FIGO stages I-III. At the time of the analysis, 83 
patients (88.3%) had no tumor recurrence. The FIGO staging results of the 
eleven patients with tumor recurrence showed that two patients (18%) were 
stage IIIb2; four patients (36%) were stage IIb2, and five patients (45%) were 
stage IIIb1. Histology results of patients' biopsies showed that three of the 
seven patients (43%) with adenocarcinoma, and only eight of the eighty-
seven patients with squamous carcinoma (9.2%), presented with tumor 
recurrence (p=0.03). Six of the 11 patients had local infiltration, of which five 
Table 1. FIGO staging of all patients (n=94) and patients with late radiation 
complications (n=15).
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were bladder and one rectum infiltration. Seven patients (7.5%) developed 
metastases, and of these, six also presented with tumor recurrence. The most 
common site of metastases was the para-aortic lymph nodes, followed by 
bone infiltration, lungs, liver and brain. Only one of the seven HIV-positive 
6
patients developed tumor recurrence (CD  count = 480 x 10  cells/L). The 
4
probability of tumor recurrence and late radiation complications at various 
time points (using survival analysis) is shown in Table 2.
3.3. Late radiation complications
Of the 94 patients in this study, 15 (16%) had RTOG/EORTC grade IV late 
rectal/bladder complications. The FIGO staging of the 15 patients who 
presented with late radiation complications, is illustrated in Table 1. Most 
patients had stages IIb2 (26.7%) and IIIb1 (40.0%) uterine cervical cancer. 
Late radiation complications occurred at a median time interval of 12.4 months 
(range 131 months) after completion of radiotherapy treatment. Of the 15 
patients who presented with late radiation complications, 10 had bladder and 
five had rectum complications. Two of the 15 patients were HIV-positive (CD  
4
6 6
counts of 550 x 10  cells/L and 480 x 10  cells/L, respectively). The crude 
incidence (grading) of first late bladder radiation complications 
(RTOG/EORTC scoring of these organs) was as follows: six patients with 
grade I, three with grade II, and one with grade III. The RTOG/EORTC grading 
for first late rectum complications were: grade I for three patients, grade II for 
one patient, and grade III for one patient. The median time for rectal 
complication development was six months (range 110 months). Late rectal 
complications varied from blood-streaked stool and rectal bleeding to proctitis. 
Bladder complications were teleangiectasia, intermittent macroscopic 
hematuria and severe frequency and dysuria.
Three of the 15 patients with late radiation complications also presented with a 
second late radiation complication. These patients first presented with late 
radiation complications of the rectum, followed by second late radiation 
Table 2. Probability of tumour recurrence and late radiation complications 
(n=94).
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complications of the bladder (n=2) and rectum (n=1). Of the three patients who 
presented with a second late radiation complication, one patient presented 
with a grade II rectum complication (increased stool frequency and bleeding), 
and the other two had grade III bladder complications (severe frequency and 
dysuria). Only one of the three patients with a second late radiation 
complication developed a third late radiation complication of the rectum 
(proctitis) and the bladder (cystitis). The patient received palliative treatment 
(medication). All of these patients were treated medically according to the 
symptoms.
4. CUMULATIVE BED TO THE TUMOR AND RECTUM
The cumulative BED to the tumor of EBRT and HDR-ICBT for the 94 patients 
had a mean value of 87.59 Gy , while the cumulative BED to the rectum had a 
10
mean of 106.20 Gy  (Table 3). The median BED  varied from 88.85 Gy  for 
3 10 10
non-bulky stage I/II disease to 86.36 Gy  for stage IIIb patients. Median 
10
cumulative BED  for the 11 patients with tumor recurrence, was 86.03 Gy , 
10 10
and 87.62 Gy  for the 83 patients with no tumor recurrence. The median 
10
cumulative BED  values did not differ significantly (p=0.68). The median 
10
cumulative BED for the rectum Gy  of the 15 patients with late radiation 
3
complications was 106.62 Gy , and 105.90Gy  in the remaining 79 patients. 
3 3
The difference between doses was not statistically significant (p=0.17).
The BED  results obtained after analysis of the fractionation schedule for 
10
dose effectiveness are summarized and compared to those of other 
13
fractionation schedules  in Table 4.
Table 3. Cumulative BED values for EBRT and HDR-ICBT (n=94).
          
            
           
            
            
          
         
  
              
          
           
           
            
           
           
            
              
        
           
              
              
             
          
          
      
     
             
          
          
          
89          
Table 4. BED values the Department of Oncotherapy, Bloemfontein 
10 
(1998 - 2003) and HDR fractionation schedules for recently published studies. 
(10)
5. DISCUSSION
5.1. Dose effectiveness
The main objective of this retrospective study was to analyze the dose 
effectiveness of the fractionation schedule implemented since 1994 at the 
Oncology Department, Bloemfontein, by calculating the BED for the 
combination of EBRT and HDR-ICBT to the tumor Gy  and the rectum Gy , 
10 3
using the linear quadratic model. Despite some radiation oncologists who 
have questioned the actual predictive role of the cumulative BED, which is 
derived by adding up the BEDs of EBRT and HDR-ICBT, our BED levels of 
fractionation scheme compared favourably with those of HDR brachytherapy 
13
fractionation schedules in published studies (Table 4).  The BED levels of 
3
fractionation scheme in a more recent study done by Chen et al.,  have also 
shown that their BED levels of fractionation were similar to those 
3
recommended by the ABS.  Standardization of HDR-ICBT on an international 
level will assist institutions in terms of comparing toxicities and outcomes in 
patients with cervical cancer, and will also allow for the exchange of 
information and uniformity in a multi-institutional randomized clinical trial that 
14
permits HDR-ICBT.
The median BED  for the 94 patients was 87.27 Gy  to the tumor. Although 
10 10
the BED  value in this study was approximately 10-15 Gy  less than in other 
10 10
2,1517
studies done in a pre-chemotherapy era,  the 3.3-year local control rate of 
88.3% for all FIGO stages and a 100% overall survival, compared well with 
reported studies (Table 4). No statistically significant differences were 
observed in the BED  values (p=0.68) of patients with local tumor recurrence 
10
(median 86.03 Gy ), compared to those with no recurrence (median 87.62 
10
Gy ). Consequently, BED  values could not be correlated with local tumor 
10 10
control.
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Although the patients in the present study received EBRT and HDR-ICBT as 
treatment modality in a pre-chemotherapy era, the American Brachytherapy 
Society recommends the addition of cisplatinum-based chemotherapy during 
pelvic EBRT. Five prospective randomized trials have demonstrated a 10-
15% increase in local control and survival without increase in complications 
5
when concurrent chemotherapy was added to radiation therapy.  A more 
18
recent study published by Patel et al.  on optimizing of HDR-ICBT schedules 
by treating patients with only two fractions of 9 Gy/fraction, has proven to be 
safe and effective with good local control, survival and manageable normal 
tissue toxicity. Thus, HDR schedule of higher dose per fraction with fewer 
treatment sessions reduces treatment burden, overall treatment time, and 
18
results in potential cost savings in a resource-limited country such as India.
5.2. Late radiation complications
19
The Brazilian Experience, as reported by Ferrigno et al.,  is one of the most 
concise HDR brachytherapy papers written to date as the authors provided 
adequate fractionation details, calculated and correlated BED to the tumor 
and late responding tissues, and prospectively studied their patients. One 
hundred and thirty-eight patients were treated with 45 Gy EBRT and four 
HDR-ICBT treatments of 6 Gy prescribed to point A. Patients treated with 
cumulative BED at rectum points above 110 Gy  had a higher, although not 
3
17
statistically significant, five-year actuarial rate of complications. Sood et al.  
reported on 49 patients with cervical cancer treated with a combination of 45 
Gy (1.8 Gy/fraction) of EBRT and 2 HDR-ICBT treatments of 9-9.5 Gy 
prescribed to point A. The median BED  at the rectal point in their study was 
3
95.5 Gy  (range 79.9-110.2 Gy ). These authors suggested that the low rate of 
3 3
rectal complications in the study could be attributed to the low BED  at the 
3
17
rectal point, although the point A doses were achieved as prescribed.  Patel et 
18
al.  have recently published their results on a prospective clinical study of 104 
patients (Stages IIB and IIIB) treated with HDR-ICBT, comparing 9 Gy per 
fraction in two fractions (Arm A) with 6.8 Gy per fraction in three fractions (ARM 
B). Grades II and III late rectal toxicities were observed in six and three 
patients respectively in Arm A and two patients and one patient respectively in 
Arm B. The three-year actuarial risk of developing grade III or IV late rectal 
toxicity was 4.5% for Arm A and 2.78% for Arm B (p=0.5463). The median total 
rectal BED received by the patients in Arm A from EBRT and HDR-ICBT, was 
18
115.3 Gy , and in Arm B it was 108.51 Gy .
3 3
In the current retrospective study, the fractionation schedule did not include 
9
the ICRU Report 38  rectal reference point, but the maximal rectal dose to the 
anterior rectal mucosa identified by contrast medium. The standard 
prescribed protocol at the Oncology Department in Bloemfontein was 2 
Gy/fraction, normalized to the highest rectum dose point to achieve a 
minimum total dose of 15 Gy to point A. The dose to point A therefore varied 
from patient to patient, and fraction to fraction. Point A is a geometric point in 
relation to the cervical os and uterine axis, and the rectal doses can be 
91          
significantly different depending on the geometry of the implant, size of 
applicators, amount of packing, source of activity and optimization with HDR-
ICBT. The median dose per fraction to point A was 3.66 Gy/fraction and the 
median total dose was 18 Gy.
The median BED  at the rectal point in this retrospective study was 106.2 Gy  
3 3
(range 93.7-113.9 Gy). Patients who developed late radiation complications 
received a median of 106.62 Gy , while those who did not develop 
3
complications received a median of 105.89 Gy . These BED  values did not 
3 3
differ significantly (p=0.17), and therefore BED  values could not be correlated 
3
with late radiation complications. The incidence and severity of late radiation 
complications were retrospectively analyzed and graded according to the 
RTOG/EORTC scoring scheme. Severe late rectal and bladder complications 
were uncommon in this study. One patient presented with grade IV 
complications (proctitis and cystitis), while 10 patients presented with late 
radiation complications of the bladder (grade I-III). This was, however, 
expected as the HDR-ICBT treatment did not include bladder shielding. Toita 
20
et al.  suggested that cumulative BED  at the rectal point should be kept below 
3
100-120 Gy  to prevent late rectal complications. At the local Oncology 
3
Department, the cumulative BED  at the rectal point (106.2 Gy ) was within 
3 3
these limits and as a result, only 16% of the 94 patients presented with late 
radiation complications.
The BED  and BED  values calculated for the fractionation schedule of this 
3 10
study were adequate. The available data indicated that it was not necessary to 
adapt the prescribed treatment protocol for patients diagnosed with stages I-
III uterine cervical cancer. The study had a three-year follow-up period, but 
13
according to Petereit et al.,  longer follow-up results would be required to 
determine if lower BED  values compromise pelvic control rates. Therefore, 
10
five-year follow-up results to determine whether or not BED  values in this 
10
study compromised pelvic control rates, are proposed. Although the median 
BED  of 87.27 Gy  to the tumor was effective (88.3% tumor control) with a low 
10 10
incidence of late radiation complications (16%), there is, however, room to 
increase the prescribed dose to the rectum from 2 Gy/fraction to 2.5 
Gy/fraction. The current fractionation schedule places a lot of emphasis on the 
rectum dose, while the dose delivered to the bladder has not been calculated. 
Considering that the bladder was affected in 10 of the 15 patients who 
presented with late radiation complications, it may be necessary to take the 
total dose to the bladder of this schedule into account.
Recently, the benefits of image-guided three-dimensional intracavitary 
radiotherapy(3D-ICR) in reducing the late complication rates have been 
21
reported for cervical cancer.  Evidence supports the use of 3D planning with 
computed tomography or magnetic resonance imaging (MRI) over 
conventional two-dimensional planning with fluoroscopic imaging, as there is 
improved anatomical delineation of structures and more accurate assessment 
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of volumetric doses.  Guidelines have been published by the Brachytherapy 
Group of the European Society for Therapeutic Radiology and Oncology 
21
(GEC ESTRO) and the American Society of Brachytherapy.
6. CONCLUSION
The findings obtained by this retrospective study suggest that 50 Gy EBRT to 
the whole pelvis combined with HDR-ICBT with a median total dose of 18 Gy 
to point A, administered in 4-6 fractions, is an effective and safe fractionation 
schedule in the treatment of FIGO stages I-III uterine cervical cancer patients, 
if undertaken in a mean treatment period of 41 days. Although this schedule 
appears to be both safe and effective, it is only a preliminary step to 
establishing windows of opportunity for BED  to tumors and BED  to rectal 
10 3
tissues.
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